Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Sanna Bastiano | EVP, Cell & Genetic Therapies | May 04 | Sale | 275.09 | 36 | 9,903 | 41,660 | May 06 04:05 PM | Arbuckle Stuart A | EVP, COO | May 02 | Sale | 263.98 | 306 | 80,778 | 64,760 | May 04 05:21 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | May 02 | Sale | 259.16 | 320 | 82,930 | 41,696 | May 04 05:10 PM | Bhatia Sangeeta N. | Director | May 02 | Sale | 258.94 | 737 | 190,842 | 5,903 | May 04 05:09 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | May 02 | Sale | 258.83 | 343 | 88,778 | 42,730 | May 04 05:07 PM | Liu Joy | SVP, General Counsel | Apr 29 | Sale | 275.41 | 120 | 33,049 | 14,334 | May 03 04:28 PM | Ambrose Kristen | SVP & Chief Accounting Officer | Apr 25 | Sale | 269.55 | 327 | 88,143 | 3,496 | Apr 27 04:05 PM | Lee Yuchun | Director | Apr 18 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 20 04:05 PM | Lee Yuchun | Director | Apr 18 | Sale | 284.23 | 2,000 | 568,467 | 1,875 | Apr 20 04:05 PM | Lee Yuchun | Director | Apr 14 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 18 04:05 PM | Lee Yuchun | Director | Apr 14 | Sale | 289.06 | 2,000 | 578,117 | 1,875 | Apr 18 04:05 PM | Lee Yuchun | Director | Apr 13 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 14 04:35 PM | LEIDEN JEFFREY M | Executive Chairman | Apr 13 | Sale | 289.04 | 15,789 | 4,563,653 | 74,160 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 13 | Sale | 287.50 | 2,000 | 575,010 | 1,875 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 12 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 12 | Sale | 281.03 | 2,000 | 562,051 | 1,875 | Apr 14 04:35 PM | Lee Yuchun | Director | Apr 11 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 12 04:07 PM | Lee Yuchun | Director | Apr 11 | Sale | 280.30 | 2,000 | 560,599 | 1,875 | Apr 12 04:07 PM | MCGLYNN MARGARET G | Director | Apr 08 | Option Exercise | 127.54 | 5,000 | 637,700 | 6,099 | Apr 12 04:05 PM | Bhatia Sangeeta N. | Director | Apr 08 | Option Exercise | 125.71 | 1,907 | 239,729 | 7,098 | Apr 12 04:05 PM | Lee Yuchun | Director | Apr 08 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 12 04:07 PM | Lee Yuchun | Director | Apr 08 | Sale | 278.57 | 2,000 | 557,141 | 1,875 | Apr 12 04:07 PM | Bhatia Sangeeta N. | Director | Apr 08 | Sale | 280.20 | 1,907 | 534,341 | 5,191 | Apr 12 04:05 PM | MCGLYNN MARGARET G | Director | Apr 08 | Sale | 280.22 | 5,000 | 1,401,080 | 1,099 | Apr 12 04:05 PM | Lee Yuchun | Director | Apr 07 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 08 05:57 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Apr 07 | Sale | 276.18 | 561 | 154,935 | 42,782 | Apr 08 04:34 PM | Lee Yuchun | Director | Apr 07 | Sale | 274.86 | 2,000 | 549,720 | 1,875 | Apr 08 05:57 PM | Lee Yuchun | Director | Apr 06 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 08 05:57 PM | Lee Yuchun | Director | Apr 06 | Sale | 271.62 | 2,000 | 543,243 | 1,875 | Apr 08 05:57 PM | Lee Yuchun | Director | Apr 05 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 06 04:59 PM | Lee Yuchun | Director | Apr 05 | Sale | 272.50 | 2,000 | 544,993 | 1,875 | Apr 06 04:59 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Apr 05 | Sale | 275.23 | 3,163 | 870,552 | 43,343 | Apr 06 05:02 PM | Lee Yuchun | Director | Apr 04 | Option Exercise | 81.54 | 2,000 | 163,080 | 3,875 | Apr 06 04:59 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Apr 04 | Sale | 267.71 | 562 | 150,452 | 46,506 | Apr 06 05:02 PM | Lee Yuchun | Director | Apr 04 | Sale | 267.72 | 2,000 | 535,431 | 1,875 | Apr 06 04:59 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | Apr 01 | Sale | 264.76 | 2,582 | 683,602 | 43,620 | Apr 05 04:06 PM | MCGLYNN MARGARET G | Director | Mar 31 | Option Exercise | 127.54 | 5,000 | 637,700 | 6,099 | Apr 04 04:05 PM | MCGLYNN MARGARET G | Director | Mar 31 | Sale | 262.27 | 5,000 | 1,311,346 | 1,099 | Apr 04 04:05 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Mar 17 | Sale | 250.11 | 2,833 | 708,572 | 47,356 | Mar 21 04:15 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | Mar 17 | Sale | 250.15 | 3,171 | 793,218 | 46,202 | Mar 21 04:12 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Mar 17 | Sale | 250.06 | 2,122 | 530,627 | 48,412 | Mar 21 04:10 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Feb 25 | Sale | 230.95 | 325 | 75,058 | 50,189 | Feb 28 05:27 PM | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Feb 18 | Sale | 231.00 | 519 | 119,889 | 53,104 | Feb 22 05:03 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 18 | Sale | 230.97 | 4,312 | 995,949 | 49,687 | Feb 22 04:51 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 14 | Sale | 232.02 | 2,444 | 567,057 | 57,438 | Feb 16 04:05 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 11 | Sale | 235.02 | 2,297 | 539,837 | 59,882 | Feb 14 04:11 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 02 | Option Exercise | 86.52 | 4,660 | 403,183 | 70,357 | Feb 03 04:06 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Feb 02 | Sale | 251.47 | 4,660 | 1,171,842 | 65,697 | Feb 03 04:06 PM | WAGNER CHARLES F JR | EVP & Chief Financial Officer | Feb 02 | Sale | 250.07 | 2,944 | 736,206 | 57,435 | Feb 03 04:29 PM | Sanna Bastiano | EVP, Cell & Genetic Therapies | Feb 02 | Sale | 250.98 | 1,040 | 261,017 | 54,952 | Feb 03 04:26 PM | MCGLYNN MARGARET G | Director | Jan 28 | Option Exercise | 127.54 | 5,000 | 637,700 | 6,099 | Feb 01 04:09 PM | MCGLYNN MARGARET G | Director | Jan 28 | Sale | 241.79 | 5,000 | 1,208,960 | 1,099 | Feb 01 04:09 PM | Sachdev Amit | EVP, Chief Patient Officer | Nov 15 | Sale | 187.19 | 51 | 9,547 | 31,928 | Nov 16 04:07 PM | Arbuckle Stuart A | EVP, COO | Nov 15 | Sale | 187.26 | 3 | 562 | 41,103 | Nov 16 04:05 PM | ALTSHULER DAVID | EVP, Global Research and CSO | Nov 15 | Sale | 187.22 | 34 | 6,365 | 33,589 | Nov 16 04:04 PM | Kewalramani Reshma | CEO & President | Aug 19 | Buy | 195.65 | 10,000 | 1,956,492 | 73,754 | Aug 23 08:30 AM | SACHS BRUCE I | Director | Aug 02 | Buy | 197.91 | 15,000 | 2,968,650 | 41,210 | Aug 04 04:05 PM | Bhatia Sangeeta N. | Director | Jun 02 | Sale | 209.69 | 559 | 117,216 | 5,191 | Jun 04 04:03 PM |
|